Business Description
Hologic Inc
NAICS : 334517
SIC : 3844
ISIN : BRH1OLBDR004
Description
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (60% of total sales, boosted by pandemic), breast health (14% of sales, suppressed by pandemic), surgical (11%), and skeletal health (1%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.97 | |||||
| Equity-to-Asset | 0.56 | |||||
| Debt-to-Equity | 0.55 | |||||
| Debt-to-EBITDA | 2.5 | |||||
| Interest Coverage | 6.94 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 3.92 | |||||
| Beneish M-Score | -2.59 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.3 | |||||
| 3-Year EBITDA Growth Rate | 86.4 | |||||
| 3-Year FCF Growth Rate | 58.2 | |||||
| 3-Year Book Growth Rate | 35.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -2.35 | |||||
| Future 3-5Y Total Revenue Growth Rate | -3.61 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 12-1 Month Momentum % | 9.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.42 | |||||
| Quick Ratio | 3.73 | |||||
| Cash Ratio | 2.82 | |||||
| Days Inventory | 121.53 | |||||
| Days Sales Outstanding | 61.37 | |||||
| Days Payable | 36.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 2.6 | |||||
| Shareholder Yield % | 3.2 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 51.65 | |||||
| Operating Margin % | 18.4 | |||||
| Net Margin % | 11.99 | |||||
| ROE % | 9.51 | |||||
| ROA % | 5.2 | |||||
| ROIC % | 8.66 | |||||
| ROC (Joel Greenblatt) % | 68.82 | |||||
| ROCE % | 9.37 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 36.38 | |||||
| Forward PE Ratio | 17.33 | |||||
| PE Ratio without NRI | 36.38 | |||||
| Shiller PE Ratio | 35.94 | |||||
| Price-to-Owner-Earnings | 35.51 | |||||
| PEG Ratio | 1.01 | |||||
| PS Ratio | 4.34 | |||||
| PB Ratio | 3.32 | |||||
| Price-to-Tangible-Book | 18.24 | |||||
| Price-to-Free-Cash-Flow | 21.03 | |||||
| Price-to-Operating-Cash-Flow | 18.19 | |||||
| EV-to-EBIT | 22.12 | |||||
| EV-to-Forward-EBIT | 14.21 | |||||
| EV-to-EBITDA | 15.21 | |||||
| EV-to-Forward-EBITDA | 12.91 | |||||
| EV-to-Revenue | 4.28 | |||||
| EV-to-Forward-Revenue | 4.2 | |||||
| EV-to-FCF | 20.77 | |||||
| Price-to-Projected-FCF | 1.08 | |||||
| Price-to-Median-PS-Value | 1.16 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.46 | |||||
| Price-to-Graham-Number | 5.43 | |||||
| Price-to-Net-Current-Asset-Value | 93.62 | |||||
| Earnings Yield (Greenblatt) % | 4.52 | |||||
| Forward Rate of Return (Yacktman) % | 26.84 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hologic Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil R$) | 20,757.419 | ||
| EPS (TTM) (R$) | 10.152 | ||
| Beta | -0.59 | ||
| Volatility % | 6.95 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (R$) | 1.849207 | ||
| 20-Day SMA (R$) | 383.78 | ||
| 12-1 Month Momentum % | 9.65 | ||
| 52-Week Range (R$) | 358.56 - 409.01 | ||
| Shares Outstanding (Mil) | 244.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hologic Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hologic Inc Stock Events
| Event | Date | Price(R$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Hologic Inc Frequently Asked Questions
What is Hologic Inc(BSP:H1OL34)'s stock price today?
The current price of BSP:H1OL34 is R$358.56. The 52 week high of BSP:H1OL34 is R$409.01 and 52 week low is R$358.56.
When is next earnings date of Hologic Inc(BSP:H1OL34)?
The next earnings date of Hologic Inc(BSP:H1OL34) is 2023-10-31 Est..
Does Hologic Inc(BSP:H1OL34) pay dividends? If so, how much?
Hologic Inc(BSP:H1OL34) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers